We have located links that may give you full text access.
Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.
Herz 1993 December
The Studies of Left Ventricular Dysfunction (SOLVD) examined the effect of an angiotensin-converting enzyme (ACE) inhibitor, enalapril on mortality and hospitalization in 6,797 patients with low ejection fraction (EF < 0.35). Patients requiring treatment for heart failure were entered to the treatment trial (n = 2,569) while those patients not receiving pharmacological treatment for heart failure were entered in the prevention trial (n = 4,228). In the treatment trial, there was a 16% (95% confidence interval [CI], 5% to 26%) reduction in mortality with the largest reduction in deaths due to progressive heart failure (22%, 95% CI, 6 to 35%). There was also a 26% (95% CI, 18 to 34%) reduction in mortality or hospitalization for worsening heart failure. In the prevention trial there was an 8% (95% CI, -8 to 21%) reduction in mortality, 12% (95% CI, -3 to 26%) reduction in cardiovascular mortality, and a 29% (95% CI, 21 to 36%) reduction in mortality or development of heart failure. In addition, there was a 20% (95% CI, 9 to 30%) reduction in mortality or hospitalization for heart failure. There were consistent effects among subgroups defined by baseline serum sodium, vasodilator use, etiology and NYHA functional class. The effect of enalapril on mortality and hospitalization for heart failure was significantly greater for patients with the lowest ejection fraction. In both trials, there were highly significant reductions in myocardial infarction (23%, 95% CI, 11 to 34%) and hospitalizations for unstable angina (20%, 95% CI, 9 to 29%).
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app